Bridging Innovation and Access: Insights from Advanced Technologies and Treatments for Diabetes 2025 and the Indian Blueprint for Diabetes Technology

The 18 th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2025) highlighted groundbreaking advancements – including closed-loop insulin delivery systems, artificial intelligence (AI)-integrated monitoring platforms, continuous glucose and ketone monitoring (CGM/CKM), and regenerative cellular therapies – that are redefining global diabetes care. While these innovations significantly enhance glycemic control, patient autonomy, and clinical decision-making, equitable access remains a critical challenge, particularly in low- and middle-income countries (LMICs). The objective of the study was to synthesize key clinical and technological insights from ATTD 2025, with a focus on their applicability in LMICs. This review evaluates the efficacy and adoption potential of automated insulin delivery (AID) systems, AI-driven decision tools, next-generation CGM/CKM devices, and beta-cell replacement strategies, while also examining regulatory, infrastructural, and ethical considerations – using India as a case study for scalable implementation. Early adoption of AID systems in pediatric populations demonstrates substantial improvements in time-in-range (TIR) and psychosocial outcomes. CKM technologies offer earlier detection of diabetic ketoacidosis, and AI-powered platforms are driving personalized, real-time diabetes management. Despite these benefits, widespread adoption in LMICs is constrained by fragmented regulatory frameworks, affordability issues, limited reimbursement, and health system disparities. India’s emerging regulatory reforms, AI sandbox programs, and expanding digital health infrastructure suggest a replicable model for contextualizing global innovations. Bridging the diabetes technology divide in LMICs requires a systems-level approach that aligns innovation with affordability, digital readiness, and policy support. Multisectoral collaboration – including regulatory adaptation, public–private partnerships, and patient-centered design – is essential to achieving inclusive, sustainable access to next-generation diabetes care.